• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性多中心 Castleman 病伴与不伴 TAFRO 综合征的淋巴结病例的临床病理比较。

The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.

机构信息

Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan.

Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.

出版信息

Hum Pathol. 2018 Jul;77:130-138. doi: 10.1016/j.humpath.2018.04.001. Epub 2018 Apr 21.

DOI:10.1016/j.humpath.2018.04.001
PMID:29684500
Abstract

Multicentric Castleman disease (MCD) is a systemic inflammatory disease potentially caused by an increase in the serum interleukin-6 (IL-6) level. Idiopathic MCD (iMCD) is histopathologically classified into three types: plasmacytic (PC), mixed, and hypervascular (hyperV) types. Recently, a unique clinical phenotype with a poor prognosis overlap with iMCD, thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly (TAFRO syndrome), has been reported from Japan, but its detailed clinicopathological features remain unclear. In this study, we performed a clinicopathological analysis of 70 nodal cases of iMCD with and without TAFRO syndrome (n = 37 versus n = 33). Compared with iMCD without TAFRO, iMCD with TAFRO showed more atrophic lymphoid follicles (LF), greater distances between follicles, increased glomeruloid vascular proliferation within the germinal center, and increased follicular dendritic cells. In addition, the hyperV type in particular demonstrated severe atrophic LF and interfollicular vascular proliferation. Among the mixed-type cases, the serum IL-6 levels in iMCD with TAFRO were significantly higher than those in iMCD without TAFRO. Furthermore, compared to iMCD without TAFRO, the numbers of immunoglobulin G4 (IgG4)-positive and CD38-positive plasma cells were significantly decreased in iMCD with TAFRO.

摘要

多中心 Castleman 病(MCD)是一种全身性炎症性疾病,可能由血清白细胞介素 6(IL-6)水平升高引起。特发性 MCD(iMCD)在组织病理学上分为 3 种类型:浆细胞型(PC)、混合性和高血管型(hyperV)。最近,日本报道了一种独特的临床表现,其预后较差,与 iMCD、血小板减少症、全身性水肿、发热、肾衰竭或网状纤维形成和器官肿大(TAFRO 综合征)重叠,但其详细的临床病理特征仍不清楚。在这项研究中,我们对伴有和不伴有 TAFRO 综合征的 70 例淋巴结 iMCD 病例(n=37 与 n=33)进行了临床病理分析。与不伴有 TAFRO 的 iMCD 相比,伴有 TAFRO 的 iMCD 显示出更多的淋巴滤泡萎缩(LF),滤泡之间的距离更大,生发中心内的血管增生呈肾小球样,滤泡树突状细胞增多。此外,高血管型尤其表现出严重的 LF 萎缩和滤泡间血管增生。在混合性病例中,伴有 TAFRO 的 iMCD 血清 IL-6 水平明显高于不伴有 TAFRO 的 iMCD。此外,与不伴有 TAFRO 的 iMCD 相比,伴有 TAFRO 的 iMCD 中 IgG4 阳性和 CD38 阳性浆细胞的数量明显减少。

相似文献

1
The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.特发性多中心 Castleman 病伴与不伴 TAFRO 综合征的淋巴结病例的临床病理比较。
Hum Pathol. 2018 Jul;77:130-138. doi: 10.1016/j.humpath.2018.04.001. Epub 2018 Apr 21.
2
The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome.滤泡辅助 T 细胞在特发性多中心 Castleman 病伴和不伴 TAFRO 综合征中的潜在作用。
Pathol Res Pract. 2019 Oct;215(10):152563. doi: 10.1016/j.prp.2019.152563. Epub 2019 Jul 26.
3
An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.伴有和不伴有TAFRO综合征的特发性多中心Castleman病的结外组织病理学分析
Pathol Res Pract. 2019 Mar;215(3):410-413. doi: 10.1016/j.prp.2018.12.025. Epub 2018 Dec 26.
4
Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).患者出现肝弯曲杆菌空肠亚种感染(特发性多中心 Castleman 病伴血小板减少、全身性水肿、发热、网状纤维纤维化和器官肿大(TAFRO)综合征)。
Pathol Int. 2019 Oct;69(10):572-579. doi: 10.1111/pin.12856.
5
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.特发性多中心 Castleman 病伴血小板减少、浮肿、发热、网状纤维纤维化、肾功能不全和器官肿大(TAFRO)临床亚型的验证性国际定义。
Am J Hematol. 2021 Oct 1;96(10):1241-1252. doi: 10.1002/ajh.26292. Epub 2021 Jul 28.
6
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.TAFRO 综合征的临床病理分析显示了一种独特的 HH V-8 阴性多中心 Castleman 病亚型。
Am J Hematol. 2016 Feb;91(2):220-6. doi: 10.1002/ajh.24242.
7
TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?TAFRO综合征:一种综合征还是多中心Castleman病的一个亚型?
Biomedicines. 2024 Mar 14;12(3):652. doi: 10.3390/biomedicines12030652.
8
Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?TAFRO 综合征是否为特发性多中心 Castleman 病的一个亚型?
Am J Hematol. 2019 Sep;94(9):975-983. doi: 10.1002/ajh.25554. Epub 2019 Jun 21.
9
International definition of iMCD-TAFRO: future perspectives.iMCD-TAFRO 的国际定义:未来展望。
J Clin Exp Hematop. 2022 Jun 28;62(2):73-78. doi: 10.3960/jslrt.21037. Epub 2022 Apr 27.
10
Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.血清干扰素诱导蛋白 10 kDa 升高与 TAFRO 综合征相关。
Sci Rep. 2017 Feb 13;7:42316. doi: 10.1038/srep42316.

引用本文的文献

1
Pathophysiology, Treatment, and Prognosis of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome: A Review.血小板减少、全身性水肿、发热、网状纤维变性/肾衰竭及器官肿大(TAFRO)综合征的病理生理学、治疗与预后:综述
Curr Issues Mol Biol. 2024 Oct 9;46(10):11255-11269. doi: 10.3390/cimb46100668.
2
Comparison of pathophysiological differences in TAFRO syndrome with or without lymphadenopathy.TAFRO 综合征伴或不伴淋巴结病的病理生理学差异比较。
J Clin Exp Hematop. 2024 Sep 28;64(3):208-215. doi: 10.3960/jslrt.24026. Epub 2024 Jul 31.
3
TAFRO Syndrome: Guidance for Managing Patients Presenting Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly.
TAFRO综合征:血小板减少、全身性水肿、发热、网状纤维增生、肾功能不全及脏器肿大患者的管理指南
Biomedicines. 2024 Jun 8;12(6):1277. doi: 10.3390/biomedicines12061277.
4
Tacrolimus Treatment for TAFRO Syndrome.他克莫司治疗TAFRO综合征
Biomedicines. 2024 May 12;12(5):1070. doi: 10.3390/biomedicines12051070.
5
TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?TAFRO综合征:一种综合征还是多中心Castleman病的一个亚型?
Biomedicines. 2024 Mar 14;12(3):652. doi: 10.3390/biomedicines12030652.
6
Epstein-Barr Virus-Positive Cutaneous and Systemic Plasmacytosis with TAFRO Syndrome-like Symptoms Successfully Treated with Rituximab.成功用利妥昔单抗治疗符合 TAFRO 综合征样症状的 EBV 阳性皮肤和全身浆细胞增多症。
Medicina (Kaunas). 2023 Jan 23;59(2):216. doi: 10.3390/medicina59020216.
7
Acute Abdomen and Adrenal Swelling as the First Manifestations of TAFRO Syndrome.TAFRO 综合征以急性腹痛和肾上腺肿胀为首发表现
Intern Med. 2023 Jun 1;62(11):1675-1681. doi: 10.2169/internalmedicine.0267-22. Epub 2022 Sep 6.
8
TAFRO Syndrome: A Disease Requiring Immediate Medical Attention.TAFRO 综合征:一种需要立即就医的疾病。
Intern Med. 2023 Jan 1;62(1):27-32. doi: 10.2169/internalmedicine.9622-22. Epub 2022 May 21.
9
Castleman disease and TAFRO syndrome.卡斯尔曼病和 TAFRO 综合征。
Ann Hematol. 2022 Mar;101(3):485-490. doi: 10.1007/s00277-022-04762-6. Epub 2022 Jan 19.
10
Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.儿童症状性和无症状性 Castleman 病的组织学和实验室特征。
Am J Clin Pathol. 2020 May 5;153(6):821-832. doi: 10.1093/ajcp/aqaa011.